Eupraxia Pharmaceuticals Inc (EPRX) - Total Liabilities

Latest as of September 2025: CA$5.43 Million CAD ≈ $3.93 Million USD

Based on the latest financial reports, Eupraxia Pharmaceuticals Inc (EPRX) has total liabilities worth CA$5.43 Million CAD (≈ $3.93 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore EPRX year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Eupraxia Pharmaceuticals Inc - Total Liabilities Trend (2017–2024)

This chart illustrates how Eupraxia Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See Eupraxia Pharmaceuticals Inc (EPRX) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Eupraxia Pharmaceuticals Inc Competitors by Total Liabilities

The table below lists competitors of Eupraxia Pharmaceuticals Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Suzhou Fushilai Pharmaceutical Co. Ltd. SHE:301258	China	CN¥211.52 Million
Interarch Building Products Limited NSE:INTERARCH	India	Rs4.20 Billion
Xiamen Goldenhome Co Ltd SHG:603180	China	CN¥3.24 Billion
Sidetrade PA:ALBFR	France	€45.89 Million
BayCom Corp NASDAQ:BCML	USA	$2.26 Billion
Wisesoft Co Ltd SHE:002253	China	CN¥406.45 Million
Chengdu Shengbang Seals Co.Ltd. SHE:301233	China	CN¥85.45 Million
Thinkingdom Media Group Ltd SHG:603096	China	CN¥104.94 Million

Liability Composition Analysis (2017–2024)

This chart breaks down Eupraxia Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Eupraxia Pharmaceuticals Inc.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	23.98	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.04	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.04	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Eupraxia Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Eupraxia Pharmaceuticals Inc (2017–2024)

The table below shows the annual total liabilities of Eupraxia Pharmaceuticals Inc from 2017 to 2024.

Year	Total Liabilities	Change
2024-12-31	CA$4.46 Million ≈ $3.23 Million	-82.53%
2023-12-31	CA$25.55 Million ≈ $18.48 Million	+76.03%
2022-12-31	CA$14.51 Million ≈ $10.50 Million	+24.36%
2021-12-31	CA$11.67 Million ≈ $8.44 Million	-49.52%
2020-12-31	CA$23.12 Million ≈ $16.72 Million	+7.94%
2019-12-31	CA$21.42 Million ≈ $15.49 Million	+49.30%
2018-12-31	CA$14.34 Million ≈ $10.38 Million	+1849.47%
2017-12-31	CA$735.82K ≈ $532.28K	--

About Eupraxia Pharmaceuticals Inc

TO:EPRX Canada Biotechnology

Market Cap

$334.14 Million

CA$461.91 Million CAD

Market Cap Rank

#14264 Global

#422 in Canada

Share Price

CA$9.12

Change (1 day)

+1.56%

52-Week Range

CA$6.94 - CA$12.50

All Time High

CA$12.50